If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVI Global Trust Regulatory News (AGT)

Share Price Information for AVI Global Trust (AGT)

Share Price is delayed by 15 minutes
Get Live Data
254.00    -3.00 (-1.17%)
Bid:
253.50
Ask:
254.50
Spread: 1.00 (0.394%)
Market Cap: £1.01b
AGT Live PriceLast checked at - London Stock Exchange

Intraday AVI Global Trust Share Chart

Monthly Factsheet

11 Jun 2025 15:47

RNS Number : 4555M
AVI Global Trust PLC
11 June 2025
Β 

Β 

AVI GLOBAL TRUST PLC

Β 

Monthly Update

Β 

AVI Global Trust plc (the "Company") presents its Update, reporting performance figures for the month ended 31 May 2025.

Β 

This Monthly Newsletter is available on the Company's website at: AGT-May-2025.pdf

Β 

This investment management report relates to performance figures to 31 May 2025.

Β 

Total Return (Β£)

Month

Calendar Yr

to date

1Y

3Y

5Y

10Y

AGT NAV

4.2%

-0.8%

0.8%

28.5%

97.6%

162.5%

MSCI ACWI

4.7%

-2.2%

7.3%

32.4%

71.7%

174.1%

MSCI ACWI ex US

3.6%

5.9%

7.4%

22.4%

50.1%

92.7%

Β 

Manager's Comment

Β 

AVI Global Trust's (AGT) NAV increased +4.2% in May.

Β 

Entain was the top contributor adding +63bps to NAV with the shares now having moved >50% from the April lows. Vivendi was also a meaningful contributor (+45bps) as the shares returned +9% - which was entirely a function of NAV growth, as shares in UMG rose +10% following a strong set of results published at end of April. Chrysalis also contributed (+42bps) and we provide an update on the investment below.

Β 

In terms of detractors shares in Rohto declined - 15% over the month following disappointing results, costing us -74bps. There were no other notable detractors to speak of.

Β 

Chrysalis

Β 

During the month, Chrysalis (CHRY) announced an update on its Capital Allocation Policy (CAP), disclosing that AVI recently wrote to the Board requesting that a continuation vote be proposed at the 2026 AGM. The letter was co-signed by other shareholders with the signatories representing 27% of the shareholder register at the time. Other shareholders comprising a material portion of the register were supportive of the letter's contents but unable to sign it due to their internal policies.

Β 

In response, the company will now put forward a resolution at the 2026 AGM (expected to be held in March) asking shareholders to reaffirm the existing CAP. If, as we expect, this is not approved by shareholders, no new investments will be made ahead of the next formal continuation vote scheduled for the 2027 AGM (noting that the company has already now committed to making no new investments prior to the 2026 CAP vote).

Β 

AVI is the largest shareholder in CHRY with a 16.9% stake held across its funds (15.0% held by AGT). We continue to engage with the Board on the company's future strategy.

Β 

Third Point Investors

Β 

During the month, Third Point Investors (TPOU) announced proposals for it to merge with a private reinsurance company wholly owned by Third Point.

Β 

It is a well-established principle within the London market that a listed investment company materially changing investment policy should offer a full exit at or close to NAV to those shareholders who do not wish to remain invested. Several aspects of the proposed deal would set worrying precedents, and we continue to engage with stakeholders.

Β 

Gerresheimer

​

In early June, Gerresheimer issued a profit warning leading to a -23% decline in the share price.

Β 

Following this we published an open letter to the Supervisory Board setting out the steps required to secure and unlock value.

Β 

The full letter can be found here: Gerresheimer - a shot of new medicine is required.

Β 

In the letter we argue that in order to secure and unlock value:

Β 

1) We believe new financial leadership is required to repair the relationship with the market and restore credibility.

Β 

2) We believe Gerresheimer should establish a capital allocation committee to oversee and review the company's capital allocation and capital structure.

Β 

3) We believe Gerresheimer should look to exit Moulded Glass with haste.

Β 

So far, we have had encouraging feedback from a number of fellow shareholders and welcome any other interested investors getting in touch.

Β 

We continue to actively engage with management and the board in the pursuit of realising Gerresheimer's considerable value.

Β 

Contributors / Detractors (in GBP)

Β 

Largest Contributors

1- month contribution

bps

% Weight

Entain

63

4.1

Mitsubishi Logistics

34

2.4

Cordiant Digital Infrastructure

36

4.5

Vivendi

43

6.4

Wacom

20

1.6

Β 

Largest Detractors

1- month contribution

bps

% Weight

Rohto Pharmaceutical

-72

3.7

Third Point Investors

-16

2.0

Jardine Matheson

-6

2.0

SK Kaken

-5

0.6

Kyoto Financial Group

-4

1.0

Β 

Β 

MUFG Corporate Governance Limited

Corporate Secretary

Β 

11 June 2025

Β 

LEI: 213800QUODCLWWRVI968

Β 

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Newsletter referred to above, is neither incorporated into nor forms part of the above announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
DOCDZGMVDMZGKZM
Date   Source Headline
9th Apr 20265:25 pmRNSTransaction in Own Shares
9th Apr 20263:31 pmRNSListing Rule 15.6.8
9th Apr 202612:25 pmRNSNet Asset Value(s)
8th Apr 20265:17 pmRNSTransaction in Own Shares
8th Apr 20261:20 pmRNSNet Asset Value(s)
7th Apr 20265:11 pmRNSTransaction in Own Shares
7th Apr 20261:54 pmRNSNet Asset Value(s)
7th Apr 202610:38 amRNSDirector Declaration
1st Apr 20265:30 pmRNSTransaction in Own Shares
1st Apr 20261:19 pmRNSNet Asset Value(s)
1st Apr 20269:51 amRNSTotal Voting Rights
31st Mar 20261:46 pmRNSNet Asset Value(s)
30th Mar 202612:56 pmRNSNet Asset Value(s)
27th Mar 20265:08 pmRNSTransaction in Own Shares
27th Mar 20261:28 pmRNSNet Asset Value(s)
26th Mar 20265:09 pmRNSTransaction in Own Shares
25th Mar 20262:38 pmRNSNet Asset Value(s)
24th Mar 20261:05 pmRNSNet Asset Value(s)
23rd Mar 202612:53 pmRNSNet Asset Value(s)
20th Mar 20265:08 pmRNSTransaction in Own Shares
20th Mar 20261:51 pmRNSNet Asset Value(s)
19th Mar 20265:20 pmRNSTransaction in Own Shares
19th Mar 202612:29 pmRNSNet Asset Value(s)
18th Mar 20265:11 pmRNSTransaction in Own Shares
18th Mar 20262:52 pmRNSNet Asset Value(s)
17th Mar 20265:14 pmRNSTransaction in Own Shares
17th Mar 202611:49 amRNSNet Asset Value(s)
16th Mar 20265:01 pmRNSTransaction in Own Shares
16th Mar 20261:42 pmRNSNet Asset Value(s)
13th Mar 20265:01 pmRNSTransaction in Own Shares
12th Mar 20265:30 pmRNSTransaction in Own Shares
11th Mar 20265:14 pmRNSTransaction in Own Shares
11th Mar 202611:31 amRNSDirector/PDMR Shareholding
11th Mar 202611:31 amRNSDirector/PDMR Shareholding
10th Mar 20264:42 pmRNSMonthly Factsheet
10th Mar 20264:42 pmRNSMonthly Factsheet
10th Mar 20261:29 pmRNSNet Asset Value(s)
9th Mar 202612:46 pmRNSNet Asset Value(s)
6th Mar 20261:45 pmRNSNet Asset Value(s)
5th Mar 20265:30 pmRNSTransaction in Own Shares
5th Mar 20261:28 pmRNSNet Asset Value(s)
4th Mar 202612:43 pmRNSNet Asset Value(s)
3rd Mar 202612:19 pmRNSNet Asset Value(s)
2nd Mar 202612:35 pmRNSNet Asset Value(s)
2nd Mar 20269:50 amRNSTotal Voting Rights
27th Feb 20263:14 pmRNSNet Asset Value(s)
26th Feb 20261:15 pmRNSNet Asset Value(s)
25th Feb 202612:32 pmRNSNet Asset Value(s)
24th Feb 20261:00 pmRNSNet Asset Value(s)
23rd Feb 20265:20 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.